Chemotherapy With Bevacizumab Does Not Affect Liver Regeneration After Portal Vein Embolization in the Treatment of Colorectal Liver Metastases
Background Blockage of vascular endothelial growth factor (VEGF) in murine models has been shown to impair liver regeneration after partial hepatectomy. The aim of this study was to evaluate the effects of chemotherapy with or without bevacizumab (monoclonal antibody anti-VEGF) on liver regeneration...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , , |
| Format: | article |
| Published: |
2008
|
| Online Access: | http://hdl.handle.net/10725/2596 http://dx.doi.org/10.1245/s10434-008-0035-7 http://link.springer.com/article/10.1245/s10434-008-0035-7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1864513458688491520 |
|---|---|
| author | Zorzi, Daria |
| author2 | Chun, Yun Shin Madoff, David C. Abdalla, Eddie K. Vauthey, Jean-Nicolas |
| author2_role | author author author author |
| author_facet | Zorzi, Daria Chun, Yun Shin Madoff, David C. Abdalla, Eddie K. Vauthey, Jean-Nicolas |
| author_role | author |
| dc.creator.none.fl_str_mv | Zorzi, Daria Chun, Yun Shin Madoff, David C. Abdalla, Eddie K. Vauthey, Jean-Nicolas |
| dc.date.none.fl_str_mv | 2008 2008-10 2015-11-17T10:07:31Z 2015-11-17T10:07:31Z |
| dc.identifier.none.fl_str_mv | 1068-9265 http://hdl.handle.net/10725/2596 http://dx.doi.org/10.1245/s10434-008-0035-7 Zorzi, D., Chun, Y. S., Madoff, D. C., Abdalla, E. K., & Vauthey, J. N. (2008). Chemotherapy with bevacizumab does not affect liver regeneration after portal vein embolization in the treatment of colorectal liver metastases. Annals of Surgical Oncology, 15(10), 2765-2772. http://link.springer.com/article/10.1245/s10434-008-0035-7 |
| dc.language.none.fl_str_mv | en |
| dc.relation.none.fl_str_mv | Annals of Surgical Oncology |
| dc.rights.*.fl_str_mv | info:eu-repo/semantics/openAccess |
| dc.title.none.fl_str_mv | Chemotherapy With Bevacizumab Does Not Affect Liver Regeneration After Portal Vein Embolization in the Treatment of Colorectal Liver Metastases |
| dc.type.none.fl_str_mv | Article info:eu-repo/semantics/publishedVersion info:eu-repo/semantics/article |
| description | Background Blockage of vascular endothelial growth factor (VEGF) in murine models has been shown to impair liver regeneration after partial hepatectomy. The aim of this study was to evaluate the effects of chemotherapy with or without bevacizumab (monoclonal antibody anti-VEGF) on liver regeneration after portal vein embolization (PVE) in the treatment of colorectal liver metastases and its possible effect on postoperative outcome after major liver resection. Methods Records of 65 consecutive patients treated with or without preoperative chemotherapy (with or without bevacizumab) and PVE for colorectal liver metastases from September 1995 to February 2007 were reviewed from a prospective database. Future liver remnant (FLR) volume, degree of FLR hypertrophy after PVE, morbidity, mortality, and survival were analyzed. Results Preoperative PVE was performed after chemotherapy in 43 patients and without chemotherapy in 22 patients. Among the 43 patients treated with chemotherapy, 26 received concurrent bevacizumab. After a median of 4 weeks after PVE, there was no difference in FLR volume increase among patients treated with or without chemotherapy. Similarly, there was no statistically significant difference in degree of FLR hypertrophy among patients treated without (mean, 10.1%) or with chemotherapy, with or without bevacizumab (8.8% and 6.8%) (P = .11). Forty-eight (74%) of 65 patients underwent extended right or right hepatectomy after PVE. No differences in morbidity and mortality were observed among patients treated with or without preoperative chemotherapy (with or without bevacizumab). Conclusion Preoperative chemotherapy with bevacizumab does not impair liver regeneration after PVE. Liver resection can be performed safely in patients treated with bevacizumab before PVE. |
| eu_rights_str_mv | openAccess |
| format | article |
| id | LAURepo_8bf23962e32b920f05bbc748fd033976 |
| identifier_str_mv | 1068-9265 Zorzi, D., Chun, Y. S., Madoff, D. C., Abdalla, E. K., & Vauthey, J. N. (2008). Chemotherapy with bevacizumab does not affect liver regeneration after portal vein embolization in the treatment of colorectal liver metastases. Annals of Surgical Oncology, 15(10), 2765-2772. |
| language_invalid_str_mv | en |
| network_acronym_str | LAURepo |
| network_name_str | Lebanese American University repository |
| oai_identifier_str | oai:laur.lau.edu.lb:10725/2596 |
| publishDate | 2008 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| spelling | Chemotherapy With Bevacizumab Does Not Affect Liver Regeneration After Portal Vein Embolization in the Treatment of Colorectal Liver MetastasesZorzi, DariaChun, Yun ShinMadoff, David C.Abdalla, Eddie K.Vauthey, Jean-NicolasBackground Blockage of vascular endothelial growth factor (VEGF) in murine models has been shown to impair liver regeneration after partial hepatectomy. The aim of this study was to evaluate the effects of chemotherapy with or without bevacizumab (monoclonal antibody anti-VEGF) on liver regeneration after portal vein embolization (PVE) in the treatment of colorectal liver metastases and its possible effect on postoperative outcome after major liver resection. Methods Records of 65 consecutive patients treated with or without preoperative chemotherapy (with or without bevacizumab) and PVE for colorectal liver metastases from September 1995 to February 2007 were reviewed from a prospective database. Future liver remnant (FLR) volume, degree of FLR hypertrophy after PVE, morbidity, mortality, and survival were analyzed. Results Preoperative PVE was performed after chemotherapy in 43 patients and without chemotherapy in 22 patients. Among the 43 patients treated with chemotherapy, 26 received concurrent bevacizumab. After a median of 4 weeks after PVE, there was no difference in FLR volume increase among patients treated with or without chemotherapy. Similarly, there was no statistically significant difference in degree of FLR hypertrophy among patients treated without (mean, 10.1%) or with chemotherapy, with or without bevacizumab (8.8% and 6.8%) (P = .11). Forty-eight (74%) of 65 patients underwent extended right or right hepatectomy after PVE. No differences in morbidity and mortality were observed among patients treated with or without preoperative chemotherapy (with or without bevacizumab). Conclusion Preoperative chemotherapy with bevacizumab does not impair liver regeneration after PVE. Liver resection can be performed safely in patients treated with bevacizumab before PVE.PublishedN/A2015-11-17T10:07:31Z2015-11-17T10:07:31Z20082008-10Articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article1068-9265http://hdl.handle.net/10725/2596http://dx.doi.org/10.1245/s10434-008-0035-7Zorzi, D., Chun, Y. S., Madoff, D. C., Abdalla, E. K., & Vauthey, J. N. (2008). Chemotherapy with bevacizumab does not affect liver regeneration after portal vein embolization in the treatment of colorectal liver metastases. Annals of Surgical Oncology, 15(10), 2765-2772.http://link.springer.com/article/10.1245/s10434-008-0035-7enAnnals of Surgical Oncologyinfo:eu-repo/semantics/openAccessoai:laur.lau.edu.lb:10725/25962026-03-31T13:57:28Z |
| spellingShingle | Chemotherapy With Bevacizumab Does Not Affect Liver Regeneration After Portal Vein Embolization in the Treatment of Colorectal Liver Metastases Zorzi, Daria |
| status_str | publishedVersion |
| title | Chemotherapy With Bevacizumab Does Not Affect Liver Regeneration After Portal Vein Embolization in the Treatment of Colorectal Liver Metastases |
| title_full | Chemotherapy With Bevacizumab Does Not Affect Liver Regeneration After Portal Vein Embolization in the Treatment of Colorectal Liver Metastases |
| title_fullStr | Chemotherapy With Bevacizumab Does Not Affect Liver Regeneration After Portal Vein Embolization in the Treatment of Colorectal Liver Metastases |
| title_full_unstemmed | Chemotherapy With Bevacizumab Does Not Affect Liver Regeneration After Portal Vein Embolization in the Treatment of Colorectal Liver Metastases |
| title_short | Chemotherapy With Bevacizumab Does Not Affect Liver Regeneration After Portal Vein Embolization in the Treatment of Colorectal Liver Metastases |
| title_sort | Chemotherapy With Bevacizumab Does Not Affect Liver Regeneration After Portal Vein Embolization in the Treatment of Colorectal Liver Metastases |
| url | http://hdl.handle.net/10725/2596 http://dx.doi.org/10.1245/s10434-008-0035-7 http://link.springer.com/article/10.1245/s10434-008-0035-7 |